A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobinai, Kensei, Klein, Christian, Oya, Naoko, Fingerle-Rowson, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/
https://www.ncbi.nlm.nih.gov/pubmed/28004361
http://dx.doi.org/10.1007/s12325-016-0451-1
_version_ 1782511308580585472
author Tobinai, Kensei
Klein, Christian
Oya, Naoko
Fingerle-Rowson, Günter
author_facet Tobinai, Kensei
Klein, Christian
Oya, Naoko
Fingerle-Rowson, Günter
author_sort Tobinai, Kensei
collection PubMed
description Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Efficacy as monotherapy has been reported in patients with relapsed/refractory indolent and aggressive non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL) of B-cell origin. Improved outcomes have also been noted when obinutuzumab is added to chemotherapy in patients with B-cell NHL, and superiority over rituximab has been reported with combination therapy in patients with CLL. Ongoing research is focusing on developing options for chemotherapy-free treatment and on new combinations of obinutuzumab with novel targeted agents.
format Online
Article
Text
id pubmed-5331088
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-53310882017-03-13 A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies Tobinai, Kensei Klein, Christian Oya, Naoko Fingerle-Rowson, Günter Adv Ther Review Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Efficacy as monotherapy has been reported in patients with relapsed/refractory indolent and aggressive non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL) of B-cell origin. Improved outcomes have also been noted when obinutuzumab is added to chemotherapy in patients with B-cell NHL, and superiority over rituximab has been reported with combination therapy in patients with CLL. Ongoing research is focusing on developing options for chemotherapy-free treatment and on new combinations of obinutuzumab with novel targeted agents. Springer Healthcare 2016-12-21 2017 /pmc/articles/PMC5331088/ /pubmed/28004361 http://dx.doi.org/10.1007/s12325-016-0451-1 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Tobinai, Kensei
Klein, Christian
Oya, Naoko
Fingerle-Rowson, Günter
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title_full A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title_fullStr A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title_full_unstemmed A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title_short A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
title_sort review of obinutuzumab (ga101), a novel type ii anti-cd20 monoclonal antibody, for the treatment of patients with b-cell malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/
https://www.ncbi.nlm.nih.gov/pubmed/28004361
http://dx.doi.org/10.1007/s12325-016-0451-1
work_keys_str_mv AT tobinaikensei areviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT kleinchristian areviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT oyanaoko areviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT fingerlerowsongunter areviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT tobinaikensei reviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT kleinchristian reviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT oyanaoko reviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies
AT fingerlerowsongunter reviewofobinutuzumabga101anoveltypeiianticd20monoclonalantibodyforthetreatmentofpatientswithbcellmalignancies

Ejemplares similares